Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
WuXi Biologics Cayman Inc (Wuxi Biologics) is a contract research, development and manufacturing organization (CRDMO). The company offers services such as mammalian services including monoclonal antibodies, bisepecific and multispecific antibodies, fc-fusion proteins, antibody fragments and others. Its microbial services include antibody fragments, enzymes, plasmid DNA, virus-like particles, among others. The company technology platforms include ultra-intensified fed-batch platform – WuXiUI, rapid research material generation – WuXian, cell line development – WuXia, continuous bioprocessing – WuXiUP, ADC development Platform – WuXiDAR4, high concentration and HTP DP platform – WuXiHigh and others. Wuxi Bio is headquartered in Wuxi, Jiangsu, China.
Headquarters
China
Address
No. 108, Meiliang Road, Mashan, Wuxi, Jiangsu, 10004
Website
www.wuxibiologics.com
No of Employees
13,252
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2269 (HKG)
Revenue (2024)
$3.0B
16.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
46.3%
(2024 vs 2023)
Market Cap*
$17.3B
Net Profit Margin (2024)
XYZ
25.4%
(2024 vs 2023)
* As of and is in US$
WuXi Biologics Cayman Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Technology Platforms: | Contract Research Development and Manufacturing Services | WuXiHybrid |
| Bispecific and Multispecific Antibodies – WuXiBody | Mammalian services: | WuXiLiAb |
| Advanced Hybridoma Platform – WuXiHybrid | Monoclonal Antibodies | WuXiUI |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company entered into a strategic collaboration agreement with Earendil Labs to create and manufacture multiple novel bispecific and multispecific antibodies and ADC candidates in Earendil Labs' pipeline targeting autoimmune disease, cancer, and other diseases. |
| 2026 | Contracts/Agreements | In February, the company signed an agreement with Vertex Pharmaceuticals Incorporated for an innovative trispecific T-cell Engager to treat B-cell mediated autoimmune diseases. |
| 2026 | New Products/Services | In January, the company introduced PatroLab, a new digital twin platform to transform bioprocess development and manufacturing. |
Competitor Comparison
| Key Parameters | WuXi Biologics Cayman Inc | AutekBio (Beijing), Inc. | Bioworkshops | Canton Biologics Co Ltd | Chime Biologics Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Wuxi | Beijing | Suzhou | Guangzhou | Wuhan |
| State/Province | Jiangsu | - | Jiangsu | Guangdong | Hubei |
| No. of Employees | 13,252 | - | - | - | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ge Li | Chairman | Executive Board | 2014 | 59 |
| Zhisheng Chen | Director; Chief Executive Officer | Executive Board | 2016 | 53 |
| Sherry Xuejun Gu, PhD | Chief Technology Officer; Executive Vice President; Director | Executive Board | 2025 | 55 |
| Ming Tu | Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 57 |
| He Wang | General Counsel; Chief Compliance Officer; Head - Legal and Compliance Department; Senior Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer